

# **2021 Finland Tumor Marker Market Assessment- Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers**

<https://marketpublishers.com/r/277812A564DEEN.html>

Date: March 2021

Pages: 535

Price: US\$ 3,500.00 (Single User License)

ID: 277812A564DEEN

## **Abstracts**

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

### **Rationale**

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric

population will further compound the growing demand for malignancy assays and the rapid market expansion.

## Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

## Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

## Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

### Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

## Contents

### I. INTRODUCTION

### II. MARKET OVERVIEW

### III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

### IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

### V. ALTERNATIVE MARKET PENETRATION STRATEGIES

### VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

### VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

1. Introduction
2. Cancer Diagnostic Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT

- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Cancer Diagnostics
- 27. Oncogenes
  - Abl/abl-bcr
  - AIB1
  - BCL-2
  - BRCA1
  - CD44
  - C-fos
  - C-myb
  - C-myc
  - CYP-17
  - Erb-B
  - HPC1
  - N-myc
  - P40
  - P51
  - P53
  - PIK3CA
  - PTI-1
  - Ras
  - Reg
  - Sis
  - Src and others
- 28. Polypeptide Growth Factors
  - Basic Fibroblast Growth Factor
  - Beta-TGF
  - Cachectin (TNT)
  - Calmodulin
  - ECFR
  - Nerve Growth Factor (NGF)
  - Epidermal Growth Factor (EGF)
  - Ornithine Decarboxylase
  - Transferrin
  - Transforming Growth Factor-Alpha
- 29. Ectopic Hormones
- 30. Colony Stimulating Factors
- 31. Lymphokines

Alpha-Interferon  
B Cell Growth Factors  
B Cell Growth Factor (BCGF)  
Gamma-Interferon  
Interleukin-1 (IL-1)  
Macrophage Activating Factor  
32. Immunohistochemical Stains  
33. Emerging Cancer Diagnostics  
N-Acetylglucosamine  
Actin  
Alpha-Actin  
Antineuronal Antibodies  
7B2  
B72.3  
Bax  
BCD-F9  
BLCA-4  
Blood Group Antigens A,B,H  
CA  
CA 72-4/TAG-72  
CA  
CA-242  
CA-549  
CAM  
CAR-3  
Cathepsin-D  
Chromogranin A and B  
Cluster 1 Antigen  
Cluster-5/5A Antigen  
CTA  
CU18  
DR-70  
DU-PAN-2  
Endometrial Bleeding Associated Factor  
Endostatin  
Epithelial Membrane Antigen  
Feulgen Hydrolysis  
Fibronectin  
FSH

(1->3)-L-fucosyltransferase  
Gastrin-Releasing Peptide (GRP)  
GDCFP-15  
Glucagon  
Glycoamines  
H23  
Her-2  
Human Carcinoma Antigen  
HPA  
HSP27  
Intermediate Filaments  
Cytokeratins/CK18/Cyfra 21-1  
Desmin  
Gliofibrillary Acid Protein  
Neurofilaments  
Vimentin  
KA  
Kinases  
KP16D3  
LAI  
Leukocyte Common Antigen  
Lewis Antigens  
Lysophosphatidic Acid (LPA)  
Ma 695/Ma  
MABDF3  
MAG  
ME1  
Minactivin  
MN/CA9  
MSA  
Mucin Cancer Antigen (MCA)  
Multiple Tumor Suppressor  
Myosin  
NEA-130  
NMP22  
OA-519  
Opioid Peptides  
P-glycoprotein  
Pancreatic Oncofetal Antigen (POA)

Placental Lactogen  
PR92  
Proliferative Index, Ki-67  
Px  
RB Inactivation/Deletion  
Ret  
SCCL  
Selectin  
Sialic Acid  
Sialyl SSEA-1/SLX  
SN10  
Somatostatin  
TA-90  
TABA  
Tachykinin  
TAG  
TPS  
Troponin  
Tubulin  
VCAM  
VEGF  
Villen and others

## **VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS**

### **IX. CURRENT AND EMERGING TECHNOLOGIES**

1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
  - a. Chronic Myelogenous Leukemia (CML)
  - b. Acute Myeloid Leukemia (AML)
  - c. Acute Lymphoblastic Leukemia (ALL)
  - d. Malignant Lymphomas Lymphoid Malignancies
  - e. Chronic Lymphocytic Leukemia (CLL)
  - f. Solid Cancers
  - g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence



6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies

## **X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS**

## **XI. COMPETITIVE PROFILES**

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott  
Affymetrix  
Beckman Coulter/Danaher  
Becton Dickinson  
bioMerieux  
Bio-Rad  
Cepheid  
DiaSorin  
Eiken Chemical  
Elitech Group  
Enzo Biochem  
Fujirebio  
Grifols  
Hologic  
Leica Biosystems  
Ortho-Clinical Diagnostics  
PerkinElmer  
Qiagen  
Roche  
Siemens Healthineers  
Takara Bio  
Thermo Fisher  
Wako and others.

## I would like to order

Product name: 2021 Finland Tumor Marker Market Assessment-Oncogenes, Bio Markers, GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/277812A564DEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/277812A564DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970